Gaudium IVF Reports Q2 FY27 Results: Revenue Up 17.9% YoY
Gaudium IVF and Women Health Ltd · Press Release · 13 Nov 2026, 2:41 am
Gaudium IVF Reports Q2 FY27 Results: Revenue Up 17.9% YoY Gaudium IVF reported Q2 FY27 revenue growth of 17.9% YoY to ₹37.4 Cr, driven by stronger patient volumes at mature hubs and initial contributions from its new South Extension centre. EBITDA declined 2.1% YoY to ₹13.5 Cr, with margins contracting 737 bps to 36.0% due to one-off rollout expenses and higher initial fixed costs for new hubs in South Extension and Gurgaon. PAT rose 0.4% YoY to ₹9.4 Cr. For H1 FY27, revenue reached ₹56.8 Cr (up 14.7% YoY) with EBITDA margin at 28.0%.
Original exchange filing (PDF)
More announcements from Gaudium IVF and Women Health Ltd
- Gaudium IVF and Women Health Limited has informed the Exchange about audio recording of Earnings Call on Unaudited Standalone and Consolidated Financial Results for the quarter and half .... · 17 Nov 2026
- Investor Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 2026 · 15 Nov 2026
- Rectification of inadvertent typographical error in the unaudited consolidated financial results for the quarter and half year ended September 30,2026 · 13 Nov 2026
- Monitoring Agency Report for quarter ended September 30, 2026 · 13 Nov 2026
- Gaudium IVF and Women Health Limited has informed the Exchange regarding revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information pursuant to Regulation 8(2) of SEBI (PIT) Regulations, 2015. · 13 Nov 2026
- Revised Code of Practices and Procedures for fair Disclosure of Unpubulished Price Sensitive Information Pursuant to Regulation 8(2) of SEBI (PIT) Regulations, 2015. · 13 Nov 2026
- Gaudium IVF and Women Health Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 · 13 Nov 2026
- Statement of Deviation(s) or variation(s) Under Regulation 32 for the quarter ended September 30, 2026. · 13 Nov 2026
